This study by Lappe et al. (JAMA, 2017) sought to determine if Vitamin D3 and calcium supplements reduce cancer risk in older women.
Randomized Controlled Trial (RCT)
This four year, double-blind, placebo-controlled, population-based, randomized clinical trial included 2,303 healthy, postmenopausal women, 55 years or older (mean age, 65.2 years). 1,156 women were randomized to receive 2000 IU/d of D3 and 1500 mg/d of calcium, and 1,147 received a placebo. The average baseline serum 25-hydroxyvitamin D level was 32.8 ng/mL; after one year levels were 43.9 ng/mL and 31.6 ng/mL in the treatment and placebo group respectively. A new diagnosis of cancer was reported in 109 participants, 45 in the treatment group and 64 in the placebo group, a difference of 1.69% that was not found to be statistically significant ([95% CI, -0.06% to 3.46%]; P = .06). Adverse events were noted in the treatment group, including renal calculi and elevated serum calcium levels. The editorial on this paper points out that this paper is in keeping with previous research that has yet to demonstrate a clear benefit to vitamin D supplementation and cancer prevention. Limitations to this study include the fact that the average baseline serum 25-hydroxyvitamin D level was 32.8 ng/mL – a level well within normal and potentially high enough to be protective from the outset. The editorial also addresses the importance of research in diverse populations. For example, African Americans may be more prone to vitamin D insufficiency. Furthermore, the study of vitamin D supplementation on specific cancers (e.g. breast or colorectal cancer) also requires further research. Both the authors and editorial conclude that further trials, including larger datasets with longer follow up, are still required.
JAMA Editorial: Vitamin D, Calcium, and Cancer: Approaching Daylight?
Please log in to access OBGFirst and the 2T Ultrasound Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
